SCHEMBL504387

SCHEMBL504387

Cc1nc(-c2ccco2)oc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.53
KDM4E B2RXH2 9/20 0.53
HPGD P15428 9/20 0.53
HSD17B10 Q99714 7/20 0.53
NPC1 O15118 5/20 0.53
RAB9A P51151 5/20 0.53
CASP3 P42574 2/20 0.53
SENP7 Q9BQF6 2/20 0.53
SENP6 Q9GZR1 2/20 0.53
ALOX5 P09917 1/20 0.51
KMT2A Q03164 4/20 0.47
MAPT P10636 4/20 0.47
MEN1 O00255 3/20 0.47
CASP1 P29466 3/20 0.47
POLB P06746 3/20 0.47
PKM P14618 3/20 0.47
USP2 O75604 2/20 0.47
LMNA P02545 2/20 0.47
ALOX12 P18054 2/20 0.47
ALOX15 P16050 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27545042 0.79 RAB9A (0.51) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL13633777 0.79 DRD2 (0.49) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL27351138 0.78 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL504421 0.78 DRD2 (0.48) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL504338 0.78 DRD2 (0.48) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL8688232 0.75 DRD2 (0.46) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL8691847 0.74 DRD2 (0.46) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL7484987 0.72 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL7484982 0.72 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL7484989 0.72 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDHSD17B10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8664226-B2 Compound having 3-heteroarylpyrimidin-4-(3H)-one structure and pharmaceutical preparation containing same KOWA COMPANY, LTD. (JP) 2014-03-04 US disclosed
EP-2420501-A1 NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME Kowa Company, Ltd. (JP) 2012-02-22 EP disclosed
US-20120028983-A1 NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME KOWA COMPANY, LTD. (JP) 2012-02-02 US disclosed
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
EP-1569916-B1 SUBSTITUTED ARALKYL DERIVATIVES CADILA HEALTHCARE LTD (IN) 2009-01-07 EP disclosed
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275956-A1 Novel Heterocyclic Compounds CYP46A1, DHCR7, NPC1L1 ALDH1A1 1358/4885KDM4E 4107/4885HPGD 724/4885
US-20120028983-A1 NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME AGTR2, AGTR1, GPR119 ALDH1A1 2511/4885KDM4E 4804/4885HPGD 991/4885
US-20090275565-A1 Substituted aralkyl derivatives UGT1A7, UGT1A10, UGT2B7 ALDH1A1 1255/4885KDM4E 4614/4885HPGD 2962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.